Antibiotic boosts radiation? small lung cancer trial tests safety

NCT ID NCT03546829

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jan 15, 2026 · Last updated May 23, 2026 · Updated 15 times

Summary

This early-stage trial is for people with non-small cell lung cancer that has progressed in a few areas (oligoprogression). It tests whether adding the antibiotic vancomycin to precision radiation is safe. Participants take vancomycin for one week before and one month after radiation. The study monitors side effects like severe diarrhea and measures immune system changes. Only 10 people will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

EARLY STAGE NON-SMALL CELL LUNG CANCER